Search results
Medicare Part D Plans Poorly Cover Adalimumab Biosimilars
Medscape· 4 days agoThis narrow coverage limits the cost-saving potential of these biosimilar competitors, expert said.
TONI KING: Enrolling in Medicare over 65 with health issues
Goshen News· 2 days agoEveryone’s finances, health, and prescriptions are different, and your health care needs, as well as...
Addus HomeCare's footprint grows through $350 million deal
Modern Healthcare· 2 hours agoAddus HomeCare's $350 million acquisition of Gentiva's personal care business will help the Texas-based company expand in four states and enter three new ones.
Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program
The National Law Review· 4 days agoAs part of its 2025 Medicare Advantage and Part D Final Rule (the Final Rule), the Centers for ...
Seniors forced to give up retirement benefits to get Medicare
Newsweek· 2 hours agoHistorically, employers who offered health benefits to retirees typically only did so in a...
What to know when enrolling in Medicare after age 65 with health issues
Las Vegas Review-Journal· 4 days agoHer cancer treatment drugs are expensive, and I am concerned about the Medicare Part D out-of-pocket...
Justices to review Meta investors’ data-harvesting suit and Medicare payments calculation -...
SCOTUSblog· 1 hour agoThe Supreme Court on Monday added two cases to its argument schedule for the 2024-25 term. In a list of orders from their private conference last week, the justices agreed to weigh in on a case ...
Traditional Medicare or Medicare Advantage? Some retirees aren’t allowed to choose
Fortune via Yahoo Finance· 8 hours agoA Medicare Advantage plan also often means lower out-of-pocket costs than the combination of...
Humira Clobbers Biosimilars in Battle for Part D Coverage
MedPage Today· 4 days agoJust about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas ...
Lilly's Alzheimer's drug faces delayed reckoning
Axios· 5 hours agoState of play: Lilly's antibody donanemab was shown to be effective in slowing Alzheimer's progression by about a third, and it could become the second...